Literature DB >> 1885073

Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease.

S H Murch1, V A Lamkin, M O Savage, J A Walker-Smith, T T MacDonald.   

Abstract

Serum tumour necrosis factor alpha (TNF alpha) concentrations were measured by enzyme linked immunoadsorbent assay in 31 normal children and during 65 episodes of clinical remission and 54 episodes of relapse in 92 children with chronic inflammatory bowel disease. An appreciable rise in TNF alpha was found only in children in relapse of ulcerative colitis and colonic Crohn's disease. The group of children with small bowel Crohn's disease in relapse did not show increases of TNF alpha above control concentrations, despite an equivalent rise in disease indices. Height velocity was depressed in children with relapse of large bowel Crohn's disease and ulcerative colitis compared with the equivalent condition in remission. The impairment of growth velocity was significantly greater in relapse of large bowel Crohn's disease and ulcerative colitis than in small bowel Crohn's disease alone, although for the subgroups in stage 1 puberty (prepubertal) the differences were not significant. Inadequate growth in chronic inflammatory bowel disease is currently ascribed to inadequate nutrition and TNF alpha may contribute to this through its cachexia inducing effects. It may, in addition, diminish pituitary growth hormone release. These results suggest that production of TNF alpha may be associated with growth failure in relapse of colonic inflammatory bowel disease.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885073      PMCID: PMC1378961          DOI: 10.1136/gut.32.8.913

Source DB:  PubMed          Journal:  Gut        ISSN: 0017-5749            Impact factor:   23.059


  48 in total

1.  Bowel necrosis induced by tumor necrosis factor in rats is mediated by platelet-activating factor.

Authors:  X M Sun; W Hsueh
Journal:  J Clin Invest       Date:  1988-05       Impact factor: 14.808

2.  Chronic TNF infusion causes anorexia but not accelerated nitrogen loss.

Authors:  H R Michie; M L Sherman; D R Spriggs; J Rounds; M Christie; D W Wilmore
Journal:  Ann Surg       Date:  1989-01       Impact factor: 12.969

3.  Tumor necrosis factor in humans.

Authors:  E J Ziegler
Journal:  N Engl J Med       Date:  1988-06-09       Impact factor: 91.245

4.  Interleukin 2 receptor expression by macrophages in inflammatory bowel disease.

Authors:  Y R Mahida; S Patel; K Wu; D P Jewell
Journal:  Clin Exp Immunol       Date:  1988-12       Impact factor: 4.330

5.  Decreased height velocity in children and adolescents before the diagnosis of Crohn's disease.

Authors:  M E Kanof; A M Lake; T M Bayless
Journal:  Gastroenterology       Date:  1988-12       Impact factor: 22.682

6.  Tumor necrosis factor-alpha inhibits growth hormone secretion from cultured anterior pituitary cells.

Authors:  P E Walton; M J Cronin
Journal:  Endocrinology       Date:  1989-08       Impact factor: 4.736

Review 7.  Cachectin: a hormone that triggers acute shock and chronic cachexia.

Authors:  K J Tracey; S F Lowry; A Cerami
Journal:  J Infect Dis       Date:  1988-03       Impact factor: 5.226

8.  Tumor necrosis factor in the serum of patients with systemic lupus erythematosus.

Authors:  C P Maury; A M Teppo
Journal:  Arthritis Rheum       Date:  1989-02

9.  Evidence for tumour necrosis factor/cachectin production in cancer.

Authors:  F Balkwill; R Osborne; F Burke; S Naylor; D Talbot; H Durbin; J Tavernier; W Fiers
Journal:  Lancet       Date:  1987-11-28       Impact factor: 79.321

10.  Cachectin/tumor necrosis factor induces cachexia, anemia, and inflammation.

Authors:  K J Tracey; H Wei; K R Manogue; Y Fong; D G Hesse; H T Nguyen; G C Kuo; B Beutler; R S Cotran; A Cerami
Journal:  J Exp Med       Date:  1988-03-01       Impact factor: 14.307

View more
  112 in total

Review 1.  Extradigestive manifestations of Helicobacter pylori infection: fact and fiction.

Authors:  G Realdi; M P Dore; L Fastame
Journal:  Dig Dis Sci       Date:  1999-02       Impact factor: 3.199

Review 2.  Chronic inflammatory bowel disease in children: a complex problem in management.

Authors:  J A Walker-Smith
Journal:  Postgrad Med J       Date:  2000-08       Impact factor: 2.401

3.  Thalidomide reduces tumour necrosis factor alpha and interleukin 12 production in patients with chronic active Crohn's disease.

Authors:  J Bauditz; S Wedel; H Lochs
Journal:  Gut       Date:  2002-02       Impact factor: 23.059

Review 4.  Therapy of Crohn's disease in childhood.

Authors:  R M Beattie
Journal:  Paediatr Drugs       Date:  2000 May-Jun       Impact factor: 3.022

5.  Cytokine profiles in peripheral blood of children and adults with Crohn disease.

Authors:  Seung Pak; Nina Holland; Elizabeth A Garnett; Elizabeth Mileti; Uma Mahadevan; Rachel Beckert; Bittoo Kanwar; Melvin B Heyman
Journal:  J Pediatr Gastroenterol Nutr       Date:  2012-06       Impact factor: 2.839

6.  Helicobacter pylori infection and growth delay in older children.

Authors:  F Perri; M Pastore; G Leandro; R Clemente; Y Ghoos; M Peeters; V Annese; M Quitadamo; A Latiano; P Rutgeerts; A Andriulli
Journal:  Arch Dis Child       Date:  1997-07       Impact factor: 3.791

Review 7.  Evaluation of new therapies for inflammatory bowel disease.

Authors:  E Carty; D S Rampton
Journal:  Br J Clin Pharmacol       Date:  2003-10       Impact factor: 4.335

Review 8.  Anti-tumour necrosis factor therapy for ulcerative colitis: evidence to date.

Authors:  Chandrashekhar Thukral; Adam Cheifetz; Mark A Peppercorn
Journal:  Drugs       Date:  2006       Impact factor: 9.546

9.  Profile of soluble cytokine receptors in Crohn's disease.

Authors:  T Gustot; A Lemmers; E Louis; C Nicaise; E Quertinmont; J Belaiche; S Roland; A Van Gossum; J Devière; D Franchimont
Journal:  Gut       Date:  2005-04       Impact factor: 23.059

10.  Significance of systemic endotoxaemia in inflammatory bowel disease.

Authors:  K R Gardiner; M I Halliday; G R Barclay; L Milne; D Brown; S Stephens; R J Maxwell; B J Rowlands
Journal:  Gut       Date:  1995-06       Impact factor: 23.059

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.